- Leqembi records best quarter since launch as Biogen raises guidanceLeqembi, the anti-amyloid Alzheimer’s drug from Eisai and Biogen, recorded $184 million in global sales in the second quarter, Biogen said Wednesday morning. It's the best showing for Leqembi since…Endpoints · 4m ago↗ source
- Boston Scientific unveils major restructuring, plots job cuts amid savings driveMedical device maker Boston Scientific has been a prolific dealmaker this year but is now taking a step back as it looks to make changes internally.